Infliximab in pediatric inflammatory bowel disease rapidly decreases fecal calprotectin levels

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 47

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

738

HTML

6300

Figures (1-2)

463

Tables (1-1)

444

Sum=7945

Dec 21, 2011 (publication date) through Dec 7, 2025

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Brief Article

World J Gastroenterol. Dec 21, 2011; 17(47): 5166-5171
Published online Dec 21, 2011. doi: 10.3748/wjg.v17.i47.5166

Table 1 Background data of 36 pediatric patients with inflammatory bowel disease treated with infliximab

Variable	Result
Age median (range)	14 (5.6-17) yr
Sex	20 boys, 16 girls
Diagnosis
CD	23
Ileitis	8
Ileocolitis	8
Colitis	7
UC	13
Left-sided colitis	4
Pancolitis	9

Maintenance medication at baseline
5-ASA	10
5-ASA + azathioprine/6-MP	12
Azathioprine/6-MP	7
None	7
Prednisolone/budesonide at baseline	19
Disease duration (median, range)	2.1 (0.4-7.6) yr

CD: Crohn’s disease; UC: Ulcerative colitis; 5-ASA: 5-aminosalicylic acid; 6-MP: 6-mercaptopurine.

Citation: Hämäläinen A, Sipponen T, Kolho KL. Infliximab in pediatric inflammatory bowel disease rapidly decreases fecal calprotectin levels. World J Gastroenterol 2011; 17(47): 5166-5171
URL: https://www.wjgnet.com/1007-9327/full/v17/i47/5166.htm
DOI: https://dx.doi.org/10.3748/wjg.v17.i47.5166